Effects of Systemic Administration of Oxytocin on Contextual Fear Extinction in a Rat Model of Post-Traumatic Stress Disorder
Authors
Abstract:
Introduction: One of the hallmark symptoms of posttraumatic stress disorder (PTSD) is the impaired extinction of traumatic memory. Single prolonged stress (SPS) has been suggested as an animal model of PTSD, since SPS rats exhibited the impaired fear extinction. Oxytocin (OXT) has been recently suggested as a potential pharmacotherapy for treatment of PTSD. In this study, using SPS rats we investigated the effects of multiple systemic administration of OXT on contextual fear extinction. Methods: SPS was conducted in three stages: restraint for 2 h, forced swim for 20 min, and diethyl ether anesthesia, and then left undisturbed in their home cage for 7 days. In the SPS group, 7 days after SPS treatment, contextual fear conditioning was performed (on day 0), and then extinction training was performed on each of four consecutive days following fear conditioning. In the sham group, the procedures were similar except that SPS treatment was not performed. Results: During extinction trial (10 min) freezing behavior was recorded. OXT (1, 10, 100 and 1000μg/kg) was administrated (I.P) immediately after each extinction trial. SPS rats exhibited significant impairment of contextual fear extinction as compared with sham rats. While there was no significant difference in the freezing levels between SPS and Sham rats 24 h after the fear conditioning, the freezing levels in SPS rats were significantly higher than those in sham rats after the second extinction training. Systemic OXT delayed fear extinction in sham rats as compared with sham-saline treated animals. No effect of OXT was found in SPS rats. Discussion: These findings indicate that increasing OXT transmission during fear memory reactivation delays fear extinction, and thus, the recommendation of OXT for PTSD treatment should be considered with caution.
similar resources
effects of systemic administration of oxytocin on contextual fear extinction in a rat model of post-traumatic stress disorder
introduction: one of the hallmark symptoms of posttraumatic stress disorder (ptsd) is the impaired extinction of traumatic memory. single prolonged stress (sps) has been suggested as an animal model of ptsd, since sps rats exhibited the impaired fear extinction. oxytocin (oxt) has been recently suggested as a potential pharmacotherapy for treatment of ptsd. in this study, using sps rats we inve...
full textEffects of systemic administration of ibuprofen on stress response in a rat model of post-traumatic stress disorder
Pro-inflammatory cytokine and brain-derived neurotrophic factor (BDNF) are modulated in post-traumatic stress disorder (PTSD). This study investigated the effects of ibuprofen (IBU) on enhanced anxiety in a rat model of PTSD induced by a single prolonged stress (SPS) procedure. The effects of IBU on inflammation and BDNF modulation in the hippocampus and the mechanisms underlying for anxiolytic...
full textPS253. Establishing a fear extinction-impaired animal model of post-traumatic stress disorder
Objective: Post-traumatic stress disorder (PTSD) is a persistent mental and emotional condition after life-threatening events. A single prolonged stress (SPS) induced animal model has demonstrated to result in neurological dysregulation and behavior abnormalities observed in PTSD. However, agmatine which was proposed as antidepressant and anxiolytic endogenous molecule was investigated in a rat...
full textXenon Impairs Reconsolidation of Fear Memories in a Rat Model of Post-Traumatic Stress Disorder (PTSD)
Xenon (Xe) is a noble gas that has been developed for use in people as an inhalational anesthestic and a diagnostic imaging agent. Xe inhibits glutamatergic N-methyl-D-aspartate (NMDA) receptors involved in learning and memory and can affect synaptic plasticity in the amygdala and hippocampus, two brain areas known to play a role in fear conditioning models of post-traumatic stress disorder (PT...
full textMy Resources
Journal title
volume 4 issue 4
pages 315- 322
publication date 2013-11
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023